Inotiv, inc. continues to expand genetic toxicology offering with support of glp assays at rockville, md, location

West lafayette, ind., july 26, 2022 (globe newswire) -- inotiv, inc. (nasdaq: notv) (the “company”, “we”, “our” or “inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the company has greatly expanded its capacity to conduct good laboratory practices (“glp”) studies for in vitro cytogenetics and bacterial mutation assays as components of the standard battery of genetic toxicology studies required to support first-in-human evaluations of novel therapeutics.
NOTV Ratings Summary
NOTV Quant Ranking